The PINK1/Parkin signaling pathway-mediated mitophagy: a forgotten protagonist in myocardial ischemia/reperfusion injury

IF 9.1 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pharmacological research Pub Date : 2024-10-15 DOI:10.1016/j.phrs.2024.107466
Xiaopeng Zhao , Zheng Wang , Lijie Wang , Tao Jiang , Dan Dong , Mingli Sun
{"title":"The PINK1/Parkin signaling pathway-mediated mitophagy: a forgotten protagonist in myocardial ischemia/reperfusion injury","authors":"Xiaopeng Zhao ,&nbsp;Zheng Wang ,&nbsp;Lijie Wang ,&nbsp;Tao Jiang ,&nbsp;Dan Dong ,&nbsp;Mingli Sun","doi":"10.1016/j.phrs.2024.107466","DOIUrl":null,"url":null,"abstract":"<div><div>Myocardial ischemia causes extensive damage, further exacerbated by reperfusion, a phenomenon called myocardial ischemia/reperfusion injury (MIRI). Nowadays, the pathological mechanisms of MIRI have received extensive attention. Oxidative stress, multiple programmed cell deaths, inflammation and others are all essential pathological mechanisms contributing to MIRI. Mitochondria are the energy supply centers of cells. Numerous studies have found that abnormal mitochondrial function is an essential \"culprit\" of MIRI, and mitophagy mediated by the phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1)/Parkin signaling pathway is an integral part of maintaining mitochondrial function. Therefore, exploring the association between the PINK1/Parkin signaling pathway-mediated mitophagy and MIRI is crucial. This review will mainly summarize the crucial role of the PINK1/Parkin signaling pathway-mediated mitophagy in MIR-induced several pathological mechanisms and various potential interventions that affect the PINK1/Parkin signaling pathway-mediated mitophagy, thus ameliorating MIRI.</div></div>","PeriodicalId":19918,"journal":{"name":"Pharmacological research","volume":"209 ","pages":"Article 107466"},"PeriodicalIF":9.1000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043661824004110","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Myocardial ischemia causes extensive damage, further exacerbated by reperfusion, a phenomenon called myocardial ischemia/reperfusion injury (MIRI). Nowadays, the pathological mechanisms of MIRI have received extensive attention. Oxidative stress, multiple programmed cell deaths, inflammation and others are all essential pathological mechanisms contributing to MIRI. Mitochondria are the energy supply centers of cells. Numerous studies have found that abnormal mitochondrial function is an essential "culprit" of MIRI, and mitophagy mediated by the phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1)/Parkin signaling pathway is an integral part of maintaining mitochondrial function. Therefore, exploring the association between the PINK1/Parkin signaling pathway-mediated mitophagy and MIRI is crucial. This review will mainly summarize the crucial role of the PINK1/Parkin signaling pathway-mediated mitophagy in MIR-induced several pathological mechanisms and various potential interventions that affect the PINK1/Parkin signaling pathway-mediated mitophagy, thus ameliorating MIRI.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
PINK1/Parkin信号通路介导的有丝分裂:心肌缺血/再灌注损伤中被遗忘的主角。
心肌缺血会造成广泛的损伤,再灌注又会进一步加剧这种损伤,这种现象被称为心肌缺血再灌注损伤(MIRI)。如今,心肌缺血再灌注损伤的病理机制已受到广泛关注。氧化应激、多种程序性细胞死亡、炎症等都是导致 MIRI 的重要病理机制。线粒体是细胞的能量供应中心。大量研究发现,线粒体功能异常是导致 MIRI 的重要 "元凶",而由磷酸酶和天丝同源物(PTEN)诱导激酶 1(PINK1)/Parkin 信号通路介导的线粒体吞噬作用是维持线粒体功能不可或缺的一部分。因此,探索 PINK1/Parkin 信号通路介导的有丝分裂与 MIRI 之间的关联至关重要。本综述将主要总结 PINK1/Parkin 信号通路介导的有丝分裂在 MIR 诱导的几种病理机制中的关键作用,以及影响 PINK1/Parkin 信号通路介导的有丝分裂从而改善 MIRI 的各种潜在干预措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmacological research
Pharmacological research 医学-药学
CiteScore
18.70
自引率
3.20%
发文量
491
审稿时长
8 days
期刊介绍: Pharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. Pharmacological research publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials); it is proud of its rapid publication of accepted papers that comprises a dedicated, fast acceptance and publication track for high profile articles.
期刊最新文献
Comparative effectiveness and safety of imported and domestic immune checkpoint inhibitors in China: A systematic review and pairwise and network meta-analyses Corrigendum to "Overcoming limitations and advancing the therapeutic potential of antibody-oligonucleotide conjugates (AOCs): Current status and future perspectives" [Pharmacol. Res. 209 (2024) 107469]. Effect of anthocyanins on metabolic syndrome through interacting with gut microbiota PPARβ/δ prevents inflammation and fibrosis during diabetic cardiomyopathy Role for the F-box proteins in heart diseases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1